

COVID-19 VACCINES:
US AND INTERNATIONAL ROLL-OUT





In our last update, we discussed US-wide and global vaccine roll-out as well as the updated studies regarding both the **Pfizer** and **Moderna** vaccines. In this update, we wanted to touch on how that roll-out has been proceeding both throughout the United States as well as globally and update on the AstraZeneca vaccine through its US Emergency Use Authorization process.

Authorized/Approved Vaccines				
Name	Vaccine Type	Primary Developers	Country of Origin	Country of Authorization / Approval
mRNA-1273	mRNA-based vaccine	Moderna	US	US
BNT162b2	mRNA-based vaccine	Pfizer, BioNTech; Fosun Pharma	Multi-national	UK, Bahrain, Canada, Mexico, US, Singapore, Oman, Saudi Arabia, Kuwait
Ad26.COV2.S	Adenovirus vaccine	Johnson & Johnson	US	US, France, Canada, Germany, Italy
AZD1222	Adenovirus vaccine	AstraZeneca	UK	UK, Bahrain, Brazil, EU, India, South Africa
CoronoVac	Inactivated vaccine (formalin with alum adjuvant)	Sinovac	China	China, Brazil, Chile, Turkey
No name announced	Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	China	China
Sputnik V	Non-replicating viral vector	Gamaleya Research Institute, Acellena Contract Drug Research and Development	Russia	Russia
BBIBP-CorV	Inactivated vaccine	Beijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	China	China, United Arab Emirates, Bahrain
Convidicea (Ad5-nCoV)	Recombinant vaccine (adenovirus type 5 vector)	CanSino Biologics	China	Mexico, China (military use), Pakistan
Covaxin	Inactivated vaccine	Bharat Biotech, ICMR	India	India
EpiVacCorona	Peptide Vaccine	Federal Budgetary Research Institute State Research Center of Russia Virology and Biotechnology	Russia	Russia

Over the last week, we have heard the encouraging results that AstraZeneca announced regarding its COVID-19 vaccine. Apparently, those results may have been based on outdated and incomplete information about the vaccine’s effectiveness. The National Institute of Allergy and Infectious Diseases stated that an independent panel of medical experts that has been helping oversee AstraZeneca’s US trial had “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data.” This sort of conflict is highly irregular and will most likely trigger extra scrutiny of the AstraZeneca vaccine by the FDA and other regulators.

Vaccines Across America

Across the U.S., enough doses have been administered to cover 19.7% of the population, and 78% of the delivered shots have been used




The largest vaccination campaign of all time is currently underway. More than 468 million doses have been administered across 135 countries. In the United States, more Americans have received at least one dose than have tested positive for the virus since the pandemic started. More Americans have now received at least one dose than



have tested positive for the virus since the pandemic started. With the current vaccination rate of approximately 2.5 million doses per day, it will take an estimated total of 5 months to cover 75% of the US population.

It is interesting to note, as of this week, almost 20% of the population has received at least one dose and with certain states like Ohio lowering the age requirement to 16 on 03/29, that number is set to increase significantly. New Mexico leads all states, with enough vaccinations to cover 26.6% of its population.

Internationally, Israel has shown that vaccines are having a strong effect. The country has led the



world in vaccination percentage and by the end of February had more than 85% of the 70+ population covered with 2 doses. Severe COVID cases and deaths declined significantly due to this. The United States still leads for total number of doses administered with 128M. China is second with almost 75M administered and the

EU, India and the UK follow. The vaccine rollout is occurred more quickly in developed countries, leading to questions regarding allotment per country. This leads us to believe that although the US should reach 75% sometime over the summer, the world may take significantly longer (years) to get to the same level.



Written by: Ram Vellanki, MD, MBA
Investment Banking Associate
Lawrence, Evans & Co., LLC
Investment Banking, Healthcare Finance, Consulting
88 E. Broad St, Suite 1750
Columbus, OH 43215
Phone 614.448.1304
rvellanki@lawrenceevans.com
www.lawrenceevans.com



Lawrence, Evans & Co., LLC. is a boutique healthcare financial advisory and investment banking firm comprised of senior level professionals who provide lead advisory services to private companies, lenders, and other parties-in-interest that are executing financial and strategic transactions. Founded in 2003, the firm provides a wide array of services such as finance and capital raising, mergers and acquisitions, management consultancy services, turnaround management and restructuring, and real estate finance and development. The firm caters to the healthcare providers and service companies (senior housing, hospital, physician services, dental, dermatology, ophthalmology, physical therapy, behavioral health, RCM, HCIT, Population Health, etc.), transportation and logistics, and business services. Transactions are typically under \$250 million or \$10 million EBITDA.

INVESTMENT BANKING & CORPORATE FINANCE	<ul style="list-style-type: none"> • Private Company Sales • Division/Subsidiary Divestitures • Distressed Transaction Advisory 	<ul style="list-style-type: none"> • Acquisition Advisory Services • Private Market Financings • LBO's and Recapitalizations
CONSULTING	<ul style="list-style-type: none"> • Strategic Options Analysis • Valuations & Financial Assessments • Interim CEO/CFO 	<ul style="list-style-type: none"> • Strategic Planning • Organizational Reviews • Expert Testimony & Opinions
TURNAROUND & RESTRUCTURING	<ul style="list-style-type: none"> • Turnaround Management • Debt Restructuring/Refinancing • Orderly Liquidations 	<ul style="list-style-type: none"> • Chief Restructuring Officer (CRO) • Bankruptcy Planning / 363 Sales • Receivership / Trustee

Represented Healthcare Transactions

 SKILLED NURSING & ASSISTED LIVING PORTFOLIO \$35,000,000 MULTI-FACILITY REFINANCING  ACTED AS ADVISOR	 MedWorx GROWTH CAPITAL RAISE  Grenville STRATEGIC ROYALTY CORP  ACTED AS ADVISOR	 MINGLE™ ANALYTICS GROWTH CAPITAL RAISE \$1,000,000  ACTED AS ADVISOR AND INVESTOR	 HealthCell Discover, Simplify, Perform PURCHASED MULTI SPECIALTY MEDICAL BILLING COMPANY  ACTED AS ADVISOR
 GLOBALNET SOLUTIONS Problem Solved SALE TO  MTBC Unique Healthcare IT Company .com  ACTED AS ADVISOR	NON-RECOURSE HOTEL CONSTRUCTION LOAN 175 ROOM HYATT HOUSE \$18,026,000  ACTED AS ADVISOR	MEDICAL BILLING AND TECHNOLOGY COMPANY \$8,000,000 SALE TO A STRATEGIC BUYER  ACTED AS ADVISOR	 RANAC Optimizing Performance & Profit For Healthcare Professionals SALE TO A STRATEGIC BUYER  ACTED AS ADVISOR

Neil Johnson
 Managing Director
 njohnson@lawrenceevans.com

Ram Vellanki, MD, MBA
 Associate
 rvellanki@lawrenceevans.com

